Hypercholesterolaemia

The PBS subsidises alirocumab and evolocumab for patients with hypercholesterolaemia.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment for hypercholesterolaemia under the National Health Act 1953, section 85 for patients with either:

  • Evolocumab for familial homozygous, familial heterozygous hypercholesterolaemia or non-familial hypercholesterolaemia
  • Alirocumab for familial heterozygous hypercholesterolaemia or non-familial hypercholesterolaemia.

Patients must be eligible for the PBS and meet the relevant restrictions criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing alirocumab and evolocumab.

Authority applications

Applying for initial treatment

Apply for initial authority approval to prescribe PBS subsidised alirocumab or evolocumab either:

Applying for initial grandfather treatment

Apply for initial grandfather authority approval to prescribe PBS subsidised alirocumab and evolocumab to treat hypercholesterolaemia either:

Applying for continuing treatment

Continuing treatment with alirocumab or evolocumab is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.

Further information

Call the PBS authority approvals line for further information.

Page last updated: 1 August 2021